Dysbiosis
The oral cavity hosts over 700 species of bacteria, one of the densest microbial communities in the human body.
When harmful, pathogenic species (Porphyromonas gingivalis, Prevotella intermedia, Filifactor alocis, Treponema denticola, Veillonella species) overgrow and crowd out protective bacteria, the result is dysbiosis — the root cause of gum disease, bad breath, and recurring decay.
Oral dysbiosis doesn't stay in the mouth — research links it to cardiovascular disease, diabetes, pregnancy complications, and systemic inflammation.
Conventional oral care (brushing, mouthwash, antibiotics) is largely indiscriminate — it doesn't distinguish harmful from beneficial bacteria, and doesn't help the mouth recolonize with protective species.
The System
A deliberate sequence, not a single sweep: first clear the pathogens, then rebuild the community that keeps them from coming back.
Phase 1
Targets and reduces harmful, pathogenic bacteria associated with gum disease, chronic bad breath, and decay, using natural compounds rather than broad-spectrum antibiotics that wipe out beneficial bacteria along with harmful ones.
Formulated around gigantol and postbiotic supernatant compounds — natural agents identified through Sarva Bio's research as having targeted antimicrobial activity against key oral pathogens.
Phase 2
Once harmful bacteria are reduced, Phase 2 supports repopulation of the oral cavity with beneficial, protective bacteria — helping the mouth rebuild a resilient, balanced microbiome rather than leaving an ecological vacuum that pathogens simply refill.
Why two phases matter
Clearing pathogens without restoring beneficial bacteria is a temporary fix. OMRS is designed to close that loop: clear, then rebuild.
Developed from real saliva testing data collected across a working dental practice.
Compounds designed to selectively target pathogenic species while sparing beneficial ones.
Patent strategy centered on gigantol and postbiotic supernatant mechanisms, covering key pathogens including Prevotella intermedia, Filifactor alocis, Treponema denticola, and Veillonella species.
Actively working with U.S. contract manufacturers to bring OMRS from formulation to scalable production.
